• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表面健康的男性医生中高密度脂蛋白胆固醇的变化与冠心病发病情况

Change in high-density lipoprotein cholesterol and incident coronary heart disease in apparently healthy male physicians.

作者信息

Rahilly-Tierney Catherine, Bowman Thomas S, Djoussé Luc, Sesso Howard D, Gaziano J Michael

机构信息

Massachusetts Veterans Epidemiology and Research Information Center, Office of Research and Development, Department of Veterans Affairs, Boston, Massachusetts, USA.

出版信息

Am J Cardiol. 2008 Dec 15;102(12):1663-7. doi: 10.1016/j.amjcard.2008.07.055.

DOI:10.1016/j.amjcard.2008.07.055
PMID:19064020
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2670559/
Abstract

The association between change in high-density lipoprotein (HDL) cholesterol and risk of subsequent coronary heart disease (CHD) is unclear. Change in HDL cholesterol was calculated in a prospective cohort of 4,501 male physicians enrolled in the Physician's Health Study (PHS) I who had HDL cholesterol measured in 1982 and again approximately 14 years later. Subjects were divided into categories of those with a decrease (>or=-2.5 mg/dl), no change (change -2.5 to 2.5 mg/dl), a small increase of 2.5 to 12.5 mg/dl, or a large increase of >or=12.5 mg/dl. Cox proportional hazards was used to examine the association between change in HDL cholesterol and incident CHD (confirmed acute myocardial infarction or cardiac death). Hazard ratios (HRs) were adjusted for age, initial HDL cholesterol, diabetes mellitus, hypertension, non-HDL cholesterol, and history of cholesterol medication. Compared with subjects with a decrease in HDL cholesterol, multivariable-adjusted HRs for CHD were 0.66 (95% confidence interval [CI] 0.40 to 1.09) in subjects with no change, 0.56 (95% CI 0.35 to 0.89) for subjects with an increase of 2.5 to 12.5 mg/dl, and 0.43 (95% CI 0.23 to 0.83) for subjects with an HDL cholesterol increase >or=12.5 mg/dl. In conclusion, our findings were consistent with an inverse graded relation between 14-year increase in HDL cholesterol and risk of subsequent CHD.

摘要

高密度脂蛋白(HDL)胆固醇变化与后续冠心病(CHD)风险之间的关联尚不清楚。在参与医师健康研究(PHS)I的4501名男性医师前瞻性队列中计算HDL胆固醇变化,这些医师在1982年测量了HDL胆固醇,并在大约14年后再次测量。受试者被分为HDL胆固醇降低(≥-2.5mg/dl)、无变化(变化范围为-2.5至2.5mg/dl)、小幅升高(2.5至12.5mg/dl)或大幅升高(≥12.5mg/dl)几类。采用Cox比例风险模型来检验HDL胆固醇变化与新发CHD(确诊的急性心肌梗死或心源性死亡)之间的关联。风险比(HRs)针对年龄、初始HDL胆固醇、糖尿病、高血压、非HDL胆固醇以及胆固醇用药史进行了调整。与HDL胆固醇降低的受试者相比,HDL胆固醇无变化的受试者发生CHD的多变量调整后HR为0.66(95%置信区间[CI]0.40至1.09),升高2.5至12.5mg/dl的受试者为0.56(95%CI0.35至0.89),HDL胆固醇升高≥12.5mg/dl的受试者为0.43(95%CI0.23至0.83)。总之,我们的研究结果与HDL胆固醇14年升高与后续CHD风险之间的反向分级关系一致。

相似文献

1
Change in high-density lipoprotein cholesterol and incident coronary heart disease in apparently healthy male physicians.表面健康的男性医生中高密度脂蛋白胆固醇的变化与冠心病发病情况
Am J Cardiol. 2008 Dec 15;102(12):1663-7. doi: 10.1016/j.amjcard.2008.07.055.
2
Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.高密度脂蛋白亚类与冠心病发病的关联:杰克逊心脏研究和弗雷明汉心脏研究后代队列研究
Eur J Prev Cardiol. 2016 Jan;23(1):41-9. doi: 10.1177/2047487314543890. Epub 2014 Jul 25.
3
Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies.残余脂蛋白胆固醇与冠心病发病:杰克逊心脏研究和弗雷明汉心脏研究后代队列研究
J Am Heart Assoc. 2016 Apr 29;5(5):e002765. doi: 10.1161/JAHA.115.002765.
4
Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease.高密度脂蛋白胆固醇和低密度脂蛋白胆固醇对冠心病风险的联合影响。
Eur J Prev Cardiol. 2013 Feb;20(1):89-97. doi: 10.1177/1741826711428242. Epub 2011 Oct 24.
5
Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: the atherosclerosis risk in communities study.高密度脂蛋白胆固醇与低密度脂蛋白胆固醇分类下的冠心病风险的相关性:社区动脉粥样硬化风险研究。
Am J Med Sci. 2011 Mar;341(3):173-80. doi: 10.1097/MAJ.0b013e3181f97e4a.
6
Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.除了低密度脂蛋白胆固醇之外:非高密度脂蛋白胆固醇水平、甘油三酯以及总胆固醇/高密度脂蛋白胆固醇比值对貌似健康的男性和女性冠心病风险的各自影响。
J Am Coll Cardiol. 2009 Dec 29;55(1):35-41. doi: 10.1016/j.jacc.2009.07.057.
7
Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study.REasons for Geographical and Racial Differences in Stroke (REGARDS) 研究中心血管疾病、癌症与极低高密度脂蛋白胆固醇之间的关联。
Cardiovasc Res. 2019 Jan 1;115(1):204-212. doi: 10.1093/cvr/cvy198.
8
High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).高密度脂蛋白胆固醇和颗粒浓度、颈动脉粥样硬化和冠状动脉事件:MESA(动脉粥样硬化的多民族研究)。
J Am Coll Cardiol. 2012 Aug 7;60(6):508-16. doi: 10.1016/j.jacc.2012.03.060. Epub 2012 Jul 11.
9
Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl.28318例低密度脂蛋白胆固醇<100mg/dl的糖尿病成人患者的代谢性血脂异常与冠心病风险
Am J Cardiol. 2015 Dec 1;116(11):1700-4. doi: 10.1016/j.amjcard.2015.08.039. Epub 2015 Sep 10.
10
Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years.70岁以上人群中胆固醇与冠心病死亡率、发病率及全因死亡率之间不存在关联。
JAMA. 1994 Nov 2;272(17):1335-40.

引用本文的文献

1
The Role of High-Density Lipoprotein Cholesterol in 2022.2022 年高密度脂蛋白胆固醇的作用。
Curr Atheroscler Rep. 2022 May;24(5):365-377. doi: 10.1007/s11883-022-01012-y. Epub 2022 Mar 10.
2
Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium.个体常规心血管危险因素和血管疾病风险的进展:PROG-IMT 联盟的见解。
Eur J Prev Cardiol. 2020 Feb;27(3):234-243. doi: 10.1177/2047487319877078. Epub 2019 Oct 16.
3
Lifestyle change and high-density lipoprotein change: the US Department of Veterans Affairs Normative Aging Study.生活方式改变与高密度脂蛋白变化:美国退伍军人事务部规范老龄化研究。
Clin Cardiol. 2012;35(7):437-42. doi: 10.1002/clc.21978. Epub 2012 Mar 8.
4
Influence of mitochondrial DNA 5178 C/A polymorphism on serum cholesterol changes: a short-term follow-up in middle-aged Japanese men.线粒体 DNA 5178C/A 多态性对血清胆固醇变化的影响:中年日本男性的短期随访。
Environ Health Prev Med. 2012 Sep;17(5):401-7. doi: 10.1007/s12199-012-0268-8. Epub 2012 Feb 19.
5
Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.依泽替米贝治疗血脂异常日本患者的疗效和安全性:ESSENTIAL 研究。
Clin Drug Investig. 2010;30(3):157-66. doi: 10.2165/11531530-000000000-00000.

本文引用的文献

1
High-density lipoprotein as a therapeutic target: a systematic review.作为治疗靶点的高密度脂蛋白:一项系统评价
JAMA. 2007 Aug 15;298(7):786-98. doi: 10.1001/jama.298.7.786.
2
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).强化降脂治疗与适度降脂治疗对老年冠心病患者心肌缺血的影响:老年患者目标评估研究(SAGE)结果
Circulation. 2007 Feb 13;115(6):700-7. doi: 10.1161/CIRCULATIONAHA.106.654756. Epub 2007 Feb 5.
3
A lifestyle program for treated hypertensives improved health-related behaviors and cardiovascular risk factors, a randomized controlled trial.一项针对已治疗高血压患者的生活方式项目改善了与健康相关的行为和心血管危险因素,一项随机对照试验。
J Clin Epidemiol. 2007 Feb;60(2):133-41. doi: 10.1016/j.jclinepi.2006.05.012. Epub 2006 Sep 28.
4
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.比较强化他汀治疗与中等强度他汀治疗的心血管结局试验的荟萃分析。
J Am Coll Cardiol. 2006 Aug 1;48(3):438-45. doi: 10.1016/j.jacc.2006.04.070. Epub 2006 Jul 12.
5
Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).冠心病患者血清高密度脂蛋白胆固醇水平治疗期增量与心脏死亡率的关系(来自苯扎贝特预防心肌梗死试验)
Am J Cardiol. 2006 Feb 15;97(4):466-71. doi: 10.1016/j.amjcard.2005.09.078. Epub 2005 Dec 22.
6
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.降低胆固醇治疗的疗效与安全性:对他汀类药物14项随机试验中90,056名参与者数据的前瞻性荟萃分析
Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27.
7
Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men.男性总胆固醇与高密度脂蛋白胆固醇比值14年变化的预测因素
Am Heart J. 2004 Jun;147(6):1033-8. doi: 10.1016/j.ahj.2003.11.018.
8
Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study.高密度脂蛋白胆固醇的生活方式决定因素:美国国立心肺血液研究所家族心脏研究
Am Heart J. 2004 Mar;147(3):529-35. doi: 10.1016/j.ahj.2003.10.033.
9
Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study.一项随机临床试验中参与者与非参与者的基线特征及死亡经历比较:医师健康研究。
Control Clin Trials. 2002 Dec;23(6):686-702. doi: 10.1016/s0197-2456(02)00235-0.
10
Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994.老年男性和女性的总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平会随着年龄增长而下降。1984年至1994年的兰乔贝纳多研究。
Circulation. 1997 Jul 1;96(1):37-43. doi: 10.1161/01.cir.96.1.37.